Healthcare Services

Epithelial ovarian cancer market forecast with key trends

April 21, 2026April 21, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Epithelial Ovarian Cancer Market In 2026 And 2030?

The market size for epithelial ovarian cancer has expanded quickly in recent years. It is anticipated to expand from $2.41 billion in 2025 to $2.8 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.2%. The expansion observed historically is attributable to factors like the prevalence of late-stage diagnoses, the utilization of chemotherapy, an aging female population, advancements in oncology infrastructure, and an increase in clinical trial activities.

The epithelial ovarian cancer market is poised for significant expansion in the upcoming years. It is forecast to attain a valuation of $5.03 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.7%. This anticipated growth throughout the projection period stems from factors such as the increasing embrace of precision oncology, advancements in biomarker-based diagnostic methods, the evolving immunotherapy pipeline, greater public awareness for early screening, and improved patient survival outcomes. Prominent developments anticipated in the forecast period encompass the rising uptake of targeted therapies, an increase in the deployment of combination treatment regimens, progress in early diagnostic technologies, the broadening scope of immunotherapy applications, and a reinforced emphasis on personalized oncology care.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/epithelial-ovarian-cancer-global-market-report

Which Strong Drivers Are Impacting The Epithelial Ovarian Cancer Market Growth?

The increasing prevalence of ovarian cancer is expected to propel the growth of the epithelial ovarian cancer market going forward. Ovarian cancer is a malignancy that begins in the ovaries, mainly affecting the epithelial cells covering their surface. The growing incidence of ovarian cancer is primarily attributed to an aging population, enhanced awareness, and improved detection rates, alongside genetic and lifestyle factors. Epithelial ovarian cancer treatment is crucial for addressing this most common and aggressive form of ovarian cancer, by targeting malignant cells to enhance survival rates and patient outcomes. For instance, in February 2024, the World Ovarian Cancer Coalition, a Canada-based non-profit organization, reported that by 2050, the global number of women diagnosed with ovarian cancer is anticipated to increase by over 55%, reaching 503,448. Annual deaths from ovarian cancer are projected to rise to 350,956, marking a nearly 70% increase from 2022. Therefore, the increasing prevalence of ovarian cancer will drive the epithelial ovarian cancer market going forward.

What Segment Categories Shape The Epithelial Ovarian Cancer Market Segment Landscape?

The epithelial ovarian cancer market covered in this report is segmented –

1) By Type Of Treatment: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Surgery

2) By Drug Class: Platinum-Based Chemotherapy Drugs, Poly (ADP-ribose) Polymerase Inhibitors, Bevacizumab, Chemotherapeutic Agents

3) By Stage Of Cancer: Early Stage, Advanced Stage

4) By Diagnosis Method: Imaging, Biopsy, Blood Tests

5) By End User: Hospitals, Clinics, Diagnostic Laboratories

Subsegments:

1) By Chemotherapy: Platinum-Based Chemotherapy, Non-Platinum Chemotherapy, Combination Chemotherapy

2) By Targeted Therapy: Monoclonal Antibodies, PARP Inhibitors, Angiogenesis Inhibitors

3) By Immunotherapy: Checkpoint Inhibitors, Cancer Vaccines, Adoptive T-Cell Therapy

4) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Progestins

5) By Surgery: Debulking Surgery, Oophorectomy, Hysterectomy

Which Trends Are Contributing To Changes In The Epithelial Ovarian Cancer Market?

Leading companies in the epithelial ovarian cancer market are concentrating on creating novel therapies, specifically FRa-directed antibody-drug conjugates (ADCs), designed to precisely target folate receptor-alpha which is abundant on cancer cells. These ADCs deliver powerful cytotoxic agents, thereby reducing damage to healthy tissues. An FRa-directed antibody-drug conjugate (ADC) functions as a targeted cancer treatment, connecting an antibody that is specific to the folate receptor-alpha (FRa) with a cytotoxic drug, ensuring the drug reaches cancer cells that display this receptor. As an example, in November 2024, AbbVie Inc., a biopharmaceutical firm from the US, obtained approval from the European Commission for ELAHERE (mirvetuximab soravtansine). This therapy is intended for adult patients suffering from folate receptor-alpha (FRa) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. ELAHERE offers an effective new therapeutic choice for individuals who have previously undergone up to three systemic treatment regimens. It targets a specific biomarker present in approximately one-third of ovarian cancer patients, thereby boosting survival rates and enhancing their quality of life. The approval also mandates a companion diagnostic tool to pinpoint appropriate candidates for this treatment.

Who Are The Companies Operating Across The Epithelial Ovarian Cancer Market Value Chain?

Major companies operating in the epithelial ovarian cancer market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Clovis Oncology Inc., Fujirebio Diagnostics Inc.

Get The Full Epithelial Ovarian Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/epithelial-ovarian-cancer-global-market-report

Which Region Holds The Highest Market Share In The Epithelial Ovarian Cancer Market?

North America was the largest region in the epithelial ovarian cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epithelial ovarian cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Epithelial Ovarian Cancer Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/epithelial-ovarian-cancer-global-market-report

Browse Through More Reports Similar to the Global Epithelial Ovarian Cancer Market 2026, By The Business Research Company

Urinary Tract Cancer Market Report 2026

https://www.thebusinessresearchcompany.com/report/urinary-tract-cancer-global-market-report

Ovarian Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/ovarian-cancer-drugs-global-market-report

Gynecological Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gynecological-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795